Trials / Terminated
TerminatedNCT04042623
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
An Open-Label Phase 2a Study to Evaluate the Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Aravive, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be enrolled. Several dose levels of AVB-S6-500 may be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVB-S6-500 | AVB-S6-500 is experimental drug |
Timeline
- Start date
- 2019-11-27
- Primary completion
- 2020-08-01
- Completion
- 2020-08-01
- First posted
- 2019-08-02
- Last updated
- 2022-02-10
- Results posted
- 2022-02-10
Locations
2 sites across 2 countries: United States, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04042623. Inclusion in this directory is not an endorsement.